MENU
+Compare
AIM
Stock ticker: ASE
AS OF
Dec 27, 11:47 AM (EDT)
Price
$0.20
Change
-$0.00 (-0.00%)
Capitalization
12.82M

AIM AIM ImmunoTech Forecast, Technical & Fundamental Analysis

a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders

Industry Biotechnology
AIM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for AIM with price predictions
Dec 26, 2024

Momentum Indicator for AIM turns negative, indicating new downward trend

AIM saw its Momentum Indicator move below the 0 level on December 18, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 101 similar instances where the indicator turned negative. In of the 101 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for AIM turned negative on December 19, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AIM entered a downward trend on November 26, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AIM's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AIM advanced for three days, in of 208 cases, the price rose further within the following month. The odds of a continued upward trend are .

AIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.401) is normal, around the industry mean (17.683). P/E Ratio (0.000) is within average values for comparable stocks, (88.299). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.761). AIM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (55.249) is also within normal values, averaging (263.109).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AIM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
AIM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

AIM is expected to report earnings to rise 100.00% to -11 cents per share on April 07

AIM ImmunoTech AIM Stock Earnings Reports
Q4'24
Est.
$-0.12
Q3'24
Beat
by $0.03
Q2'24
Beat
by $0.09
Q1'24
Est.
$-0.12
Q4'23
Missed
by $0.14
The last earnings report on November 19 showed earnings per share of -5 cents, beating the estimate of -8 cents. With 26.52K shares outstanding, the current market capitalization sits at 12.82M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2117 SW Highway 484
Phone
+1 352 448-7797
Employees
28
Web
https://www.aimimmuno.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RAIL9.550.65
+7.30%
FreightCar America
WEAV16.080.07
+0.44%
Weave Communications
UAA8.450.03
+0.36%
Under Armour
UMC6.67-0.15
-2.20%
United Microelectronic Corp
COSM0.63-0.03
-4.50%
Cosmos Health

AIM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AIM has been loosely correlated with HOTH. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if AIM jumps, then HOTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AIM
1D Price
Change %
AIM100%
+3.08%
HOTH - AIM
33%
Loosely correlated
-3.43%
SLN - AIM
29%
Poorly correlated
+1.00%
ELVN - AIM
26%
Poorly correlated
-1.90%
VRCA - AIM
24%
Poorly correlated
-5.42%
EDSA - AIM
24%
Poorly correlated
+3.43%
More